SEC EDGAR COMPANY RESEARCH

ELI LILLY & Co

LLYNYSECIK 0000059478

Pharmaceutical Preparations

Compare →
DATA COVERAGE7 metrics62 filings cached
Revenue$65.18B2025-12-31
Net Income$20.64B2025-12-31
Total Assets$112.48B2025-12-31
Equity$26.54B2025-12-31
Operating Cash Flow$16.81B2025-12-31
Diluted EPS$22.952025-12-31
DETERMINISTIC METRICS

Calculated from SEC facts

Net margin31.7%
Operating margin—
Free cash flow—
MarketHalo calculations use standardized SEC XBRL facts. Values may differ from company-defined non-GAAP measures.
WHAT CHANGED?

Latest annual period vs prior annual period

Revenue$65.18B+44.7% vs 2024-12-31
Net Income$20.64B+94.9% vs 2024-12-31
Assets$112.48B+42.9% vs 2024-12-31
Operating Cash Flow$16.81B+90.7% vs 2024-12-31
FINANCIAL HISTORY

Annual standardized XBRL facts

Metric20252025-12-3120242024-12-3120232023-12-3120222022-12-3120192019-12-31
Revenue $65.18B $45.04B — — —
Gross Profit — — — — —
Operating Income — — — — —
Net Income $20.64B $10.59B — — $1.50B
Operating Cash Flow $16.81B $8.82B $4.24B — —
Capital Expenditures — — — — —
Assets $112.48B $78.72B $64.01B — —
Liabilities — — — — —
Equity $26.54B $14.27B $10.86B $10.78B —

Source & methodology

Source: SEC EDGAR. MarketHalo caches company metadata and standardized XBRL facts and links to the original filing on SEC.gov. Filing documents are not mirrored here. Calculated metrics are deterministic MarketHalo calculations and are not investment advice.